康方生物-B(9926.HK)漲超7% 全球首創PD-1/VEGF雙抗獲批II期臨牀
格隆匯11月4日丨康方生物-B盤初明顯走強,一度漲超7%報40.5港元,市值330億港元。公司11月2日公吿稱,自主研發的新型腫瘤免疫治療藥物PD-1/VEGF雙特異性抗體(研發代號:AK112)獲中國國家藥監局藥品審評中心(CDE)批准,開展單藥或聯合化療新輔助╱輔助治療可切除非小細胞肺癌(“NSCLC”)的II期臨牀研究。據悉,AK112是率先進入III期臨牀研究階段的全球首創雙特異性抗體藥物。AK112是基於康方生物TETRABODY技術設計的PD-1/VEGF雙抗,可阻斷PD-1與PD-L1、PD-L2的結合,以及VEGF與VEGF受體的結合。PD-1抗體與VEGF阻斷劑的聯合療法已在多種瘤種(如腎細胞癌、非小細胞肺癌和肝細胞癌)中顯示出強大的療效。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.